Percent of total CD34+/CD19+/CXCR4- cells analyzed
Cells . | Percentage . |
|---|---|
| CD16+/CD133- | 10.5 ± 4.3 |
| CD16-/CD133+ | 4.6 ± 4.5 |
| CD16+/CD90- | 9.3 ± 4.4 |
| CD33+/CD127- | 4.5 ± 2.3 |
| CD33-/CD127+ | 12.0 ± 1.8 |
| CD33-/CD117+ | 16.0 ± 1.3 |
| CD127+/CD117- | 7.0 ± 1.6 |
| CD127-/CD117+ | 15.6 ± 3.5 |
Cells . | Percentage . |
|---|---|
| CD16+/CD133- | 10.5 ± 4.3 |
| CD16-/CD133+ | 4.6 ± 4.5 |
| CD16+/CD90- | 9.3 ± 4.4 |
| CD33+/CD127- | 4.5 ± 2.3 |
| CD33-/CD127+ | 12.0 ± 1.8 |
| CD33-/CD117+ | 16.0 ± 1.3 |
| CD127+/CD117- | 7.0 ± 1.6 |
| CD127-/CD117+ | 15.6 ± 3.5 |
Values reported for each phenotype are the mean ± SD from 3 independent measurements collected from 3 different BM samples from healthy volunteer donors. All other phenotypic combinations obtained with these analyses were less than 3% of total CD34+/CD19+/CXCR4- cells.